Other substances

Lumefantrine

An antimalarial fluorene.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
3
 AI-suggested references
1
 Clinical trials

General information

Lumefantrine on PubChem

Marketed as

COARTEM (fixed dose with ARTEMETHER)

 

Structure image - Lumefantrine

CCCCN(CCCC)CC(C1=CC(=CC\2=C1C3=C(/C2=C/C4=CC=C(C=C4)Cl)C=C(C=C3)Cl)Cl)O

Supporting references

Link Tested on Impact factor Notes Publication date
In silico identification of drug candidates against COVID-19
3CLpro RdRpol 		in silico 2.11

Predicted to inhibit the SARS-CoV-2 3C-like protease.

 Oct/20/2020

AI-suggested references

Link Publication date
In Vitro Evaluation of the Antiviral Activity of Methylene Blue Alone or in Combination against SARS-CoV-2.
Jul/06/2021
Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate.
Aug/14/2020
Anti-SARS-CoV-2 Potential of Artemisinins In Vitro
Feb/09/2022

Clinical trials

ID Title Status Phase Start date Completion date
NCT04695197 Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso Recruiting Phase 3 Jan/08/2021 Jul/31/2023
  • Alternative id - 20-063|202009642148520
  • Interventions - Drug: Artemether-lumefantrine (AL)|Drug: Pyronaridine-artesunate (PA)
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Ouagadougou Hospitals, Ouagadougou, Burkina Faso|Kisumu County Referral Hospital, Kisumu, Kenya
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 142
  • Age - 6 Months to 100 Years   (Child, Adult, Older Adult)
  • Outcome measures - Incidence of SARS-CoV-2 clearance|Median viral load of SARS-CoV-2|Cumulative incidence of SARS-CoV-2 clearance|Time to clearance of nasal SARS-CoV-2|Cumulative seroconversion rates (IgG, IgM, IgA)|IgG, IgM, IgA antibody titres against SARS-CoV-2|IL-6, IL-7, IL-10, TNF-alpha and Interferon-Gamma|CRP and angiotensin-2, angiopoietin-1 and angiopoietin-2|Genomic responses to SARS-CoV-2 infection|Cellular immune responses to SARS-CoV-2 infection|The clinical and parasitological antimalarial treatment response|COVID-19 disease severity|COVID-19 disease duration|COVID-19 fever duration|COVID-19 respiratory symptoms duration|COVID-19 disease duration in days|Treatment-related adverse events, serious adverse events, and adverse events resulting in treatment discontinuation
Export (.csv)